Precision Medicine

VERAXA Biotech is betting its future on its proprietary BiTAC technology, a strategic pivot that sharpens its focus amid a volatile market for cancer therapies.

YD Bio is expanding its U.S. lab network, but the real story is its strategy: turning diagnostic tests into a vast data engine to power the future of cancer research.

Molecular Partners and Orano Med begin human trials for a novel radiopharmaceutical, hoping to unlock a new front against small cell lung cancer.

Behind the headlines of cancer breakthroughs lies a booming market for specialized research firms. Discover how CROs are becoming the new engine of oncology innovation.

A surge in biotech innovation is set to transform the high-grade glioma market. With a pipeline of targeted drugs and vaccines, a once-stagnant field is now a beacon of hope.

A new company is launching an AI-powered specialty to detect cancer before it forms. But can this personalized, oncologist-led model overcome hurdles of cost and access?

A new transatlantic partnership leverages AI and a £5.25M philanthropic gift to accelerate the discovery of kinder, more effective treatments for children.

A breakthrough melanoma test from SkylineDx has earned rare dual recognition, promising to reshape patient care by reducing unnecessary surgeries.

The FDA approved Orca Bio's revolutionary cell therapy, promising better outcomes for cancer patients. But the real test lies beyond the science.

Once a quiet niche, the wAIHA market is now a battleground for J&J, Sanofi, and Novartis, with a 14.4% growth forecast and a new class of drugs.

Exact Imaging's U.S. expansion signals a major shift. With technology rivaling MRI, micro-ultrasound is poised to make precision diagnostics more accessible.

Allarity Therapeutics just secured a patent until 2042 for its cancer diagnostic. Is this the key to unlocking personalized treatment or a risky biotech bet?

Plus Therapeutics rebrands to Cerenome, signaling a major pivot to an integrated platform combining diagnostics, radiotherapeutics, and AI for CNS cancers.

Landmark 2-year study shows an AI diagnostic for diabetic kidney disease actively improves patient outcomes, validating a new era of precision medicine.

For patients with inoperable brain tumors, new diagnostic guidelines offer hope by validating CSF profiling, a disruptive technology poised to redefine care.

A landmark public-private partnership brings next-gen proton therapy to Portugal, ending medical exile for patients and creating a new European oncology hub.

A retired NYC prosecutor's daily commute to NJ for cancer treatment reveals a larger story about specialized tech, patient choice, and a shifting healthcare landscape.

GuideAI Health's new AI platform just hit the public market. It promises to find hidden vascular disease in routine scans, but can it navigate the risks?

At the Global Dairy Congress, Yili Group didn't just win awards; it showcased a new future for dairy—one driven by precision nutrition and R&D.

A wave of precision drugs for Nephrotic Syndrome is set to transform patient lives and a quiet $400M market, revealing a major shift in pharma strategy.